Zhou Ya, Lan Yanqiu, Zhang Qiang, Song Jifang, He Juan, Peng Na, Peng Xingqiao, Yang Xinxin
Department of Oncology, Chongqing General Hospital, Chomgqing, China.
Department of Oncology, 66307Army Medical Center of PLA, Chongqing, China.
Phlebology. 2022 May;37(4):279-288. doi: 10.1177/02683555211069772. Epub 2022 Feb 24.
Totally implantable venous access port (TIVAP) is a completely closed intravenous infusion system that stays in the human body for a long time. It is used for the infusion of strong irritating or hyperosmotic drugs, nutritional support treatment, blood transfusion and blood specimen collection, and other purposes. There are two common ways of TIVAP: internal jugular vein implantation and subclavian vein implantation. However, the postoperative complications of the two implantation methods are quite different, and there is no recommended implantation method in the relevant guidelines. Therefore, we conducted a meta-analysis to evaluate the difference in complications of the two implantation methods, and choose the better implantation method.
Computer search in PubMed, Embase, Web of Science, and Cochrane Library database was conducted for randomized controlled trials (RCTs) from the establishment of the database to October 2021. Two researchers independently screened the literature according to the inclusion and exclusion criteria, extracted data, and evaluated the risk of bias in the included studies. RevMan5.4 software was used for meta-analysis.
A total of 1086 patients in five studies were finally included. The results of meta-analysis showed that there was no significant difference in the incidence of infection (RR = 0.80, 95% CI: 0.43-1.48, = .47), catheter blockage (RR = 0.72, 95% CI: 0.15-3.46, = .68), port squeeze (RR = 1.07, 95% CI: 0.14-8.02, = .95), catheter-related thrombosis (RR = 0.86, 95% CI: 0.22-3.38, = 0.83), catheter displacement (RR = 0.50, 95% CI: 0.22-1.12, = .09), extravasation (RR = 0.12, 95% CI: 0.01-2.15, = .15), and catheter rupture (RR = 3.77, 95% CI: 0.16-89.76, = .41) between the two implantation paths.
There is little difference in the complication rate of TIVAP between internal jugular vein insertion and subclavian vein insertion. Due to the small number of included studies, there are certain limitations, and more studies need to be included for analysis in the future.
完全植入式静脉输液港(TIVAP)是一种长期留置在人体内的完全封闭的静脉输液系统。它用于输注强刺激性或高渗性药物、营养支持治疗、输血及血标本采集等。TIVAP常见的植入途径有两种:颈内静脉植入和锁骨下静脉植入。然而,两种植入方法的术后并发症差异较大,相关指南中尚无推荐的植入方法。因此,我们进行了一项荟萃分析,以评估两种植入方法并发症的差异,并选择更好的植入方法。
通过计算机检索PubMed、Embase、Web of Science和Cochrane Library数据库,收集自建库至2021年10月的随机对照试验(RCT)。两名研究人员根据纳入和排除标准独立筛选文献、提取数据,并评估纳入研究的偏倚风险。采用RevMan5.4软件进行荟萃分析。
最终纳入5项研究共1086例患者。荟萃分析结果显示,两种植入途径在感染发生率(RR = 0.80,95%CI:0.43 - 1.48,P = 0.47)、导管堵塞(RR = 0.72,95%CI:0.15 - 3.46,P = 0.68)、输液港挤压(RR = 1.07,95%CI:0.14 - 8.02,P = 0.95)、导管相关血栓形成(RR = 0.86,95%CI:0.22 - 3.38,P = 0.83)、导管移位(RR = 0.50,95%CI:0.22 - 1.12,P = 0.09)、渗漏(RR = 0.12,95%CI:0.01 - 2.15,P = 0.15)及导管破裂(RR = 3.77,95%CI:0.16 - 89.76,P = 0.41)方面差异均无统计学意义。
颈内静脉植入与锁骨下静脉植入TIVAP的并发症发生率差异不大。由于纳入研究数量较少,存在一定局限性,未来还需要纳入更多研究进行分析。